GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

Search

AstraZeneca PLC

Fechado

SetorSaúde

10,766 0.71

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10694

Máximo

10782

Indicadores-chave

By Trading Economics

Rendimento

1.3B

2.9B

Vendas

-1.3B

14B

P/E

Médio do Setor

28.734

51.198

EPS

148.337

Rendimento de Dividendos

2.29

Margem de lucro

21.46

Funcionários

94,300

EBITDA

648M

5.1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+23.67% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.29%

2.40%

Próximos Ganhos

29 de jul. de 2025

Próxima data de ex-dividendo

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-18B

164B

Abertura anterior

10765.29

Fecho anterior

10766

Sentimento de Notícias

By Acuity

36%

64%

112 / 380 Ranking em Healthcare

AstraZeneca PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2025, 09:36 UTC

Grandes Movimentos do Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 de abr. de 2025, 10:14 UTC

Ganhos

Correction to AstraZeneca Update

29 de abr. de 2025, 09:15 UTC

Ganhos

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 de abr. de 2025, 08:12 UTC

Ganhos

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 de abr. de 2025, 06:32 UTC

Ganhos

AstraZeneca Sales, Earnings Rise

24 de mar. de 2025, 03:15 UTC

Grandes Movimentos do Mercado

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New -2-

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 de mai. de 2025, 06:09 UTC

Aquisições, Fusões, Aquisições de Empresas

AstraZeneca Completes Acquisition of EsoBiotec

12 de mai. de 2025, 12:07 UTC

Conversa de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 de mai. de 2025, 07:20 UTC

Conversa de Mercado

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 de mai. de 2025, 15:20 UTC

Ganhos

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 de abr. de 2025, 13:09 UTC

Conversa de Mercado
Ganhos

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 de abr. de 2025, 08:04 UTC

Conversa de Mercado
Ganhos

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 de abr. de 2025, 06:05 UTC

Ganhos

AstraZeneca 1Q Core EPS $2.49

29 de abr. de 2025, 06:04 UTC

Ganhos

AstraZeneca 1Q Net Pft $2.92B

29 de abr. de 2025, 06:02 UTC

Ganhos

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca Backs 2025 View

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q EPS $1.87

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Rev $13.59B

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Oper Pft $3.67B

29 de abr. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 de abr. de 2025, 09:55 UTC

Conversa de Mercado

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 de abr. de 2025, 07:23 UTC

Conversa de Mercado

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 de abr. de 2025, 08:41 UTC

Conversa de Mercado

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 de abr. de 2025, 08:36 UTC

Conversa de Mercado

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 de abr. de 2025, 07:51 UTC

Conversa de Mercado

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 de mar. de 2025, 09:31 UTC

Ações em Alta

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Comparação entre Pares

Variação de preço

AstraZeneca PLC Previsão

Preço-alvo

By TipRanks

23.67% parte superior

Previsão para 12 meses

Média 13,232.62 GBX  23.67%

Máximo 16,500 GBX

Mínimo 10,900 GBX

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

15 ratings

11

Comprar

4

Manter

0

Vender

Sentimento

By Acuity

112 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.